Loading
companiesCompany
Fujirebio
The Japanese immunoassay company, part of H.U. Group, whose Malvern, Pennsylvania laboratory holds the original CA 19-9 and CA-125 tumour marker assays and licenses the antibodies to the big analyser makers.
Also called: Fujirebio DiagnosticsH.U. Group
Overview
Fujirebio is a Tokyo-based in vitro diagnostics company within H.U. Group Holdings. Its United States subsidiary, Fujirebio Diagnostics in Malvern, Pennsylvania, descends from Centocor Diagnostics, where the CA 19-9 and CA-125 immunoassays were developed in the early 1980s, and it still supplies the reference antibodies and assays (CA 19-9, CA-125 II, HE4, CYFRA 21-1, ProGRP) that run on its own Lumipulse analysers and, under licence, on the platforms of other manufacturers. The company is also a major supplier of Alzheimer's disease biomarker tests, and its oncology business centres on ovarian, pancreatic and lung cancer markers.
Similar pages
- TermCA-125
Shares Serum tumour markers: proper use and misuse, Ovarian cancer.
- TermTumour marker
Shares Serum tumour markers: proper use and misuse, Ovarian cancer, Pancreatic ductal adenocarcinoma.
- TargetMUC16 (CA-125)
Shares Serum tumour markers: proper use and misuse, Ovarian cancer, Pancreatic ductal adenocarcinoma.
- TrialUKCTOCS
Shares Serum tumour markers: proper use and misuse, Ovarian cancer.
- TargetCEACAM5
Shares Serum tumour markers: proper use and misuse, Non-small-cell lung cancer.